AbbVie (ABBV) Stock Price, News & Analysis

Company Overview

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health. Historically, the company has been best known for Humira (adalimumab), a leading therapy for several autoimmune diseases. AbbVie’s broader commercial and development lineup has included oncology medicines such as Imbruvica and Venclexta, as well as newer immunology treatments and specialty products. The 2020 acquisition of Allergan expanded AbbVie’s offerings into aesthetics and eye care, adding well-known products such as Botox to its portfolio and diversifying its revenue and clinical focus.

AbbVie markets its products globally and maintains research, development and commercial operations in numerous regions around the world. The company invests heavily in clinical development and collaborates with academic institutions, biotechnology companies and other partners to advance its pipeline. AbbVie is led by Chairman and Chief Executive Officer Richard A. Gonzalez, and its strategic priorities emphasize innovation in specialty medicines, lifecycle management of key assets and expansion into adjacent therapeutic and commercial areas through acquisition and partnership.

Key Stats

• Today's Range: $211.51 to $216.50
• 50-Day Range: $197.24 to $218.66
• 52-Week Range: $181.73 to $244.81
• Volume: 4.86 million shs
• Average Volume: 5.24 million shs
• Market Capitalization: $374.71 billion
• P/E Ratio: 104.62
• Dividend Yield: 3.26%
• Price Target: $253.43
• Consensus Rating: Moderate Buy

AbbVie Stock Analysis - MarketRank™

AbbVie scored higher than 97% of companies evaluated by MarketBeat, and ranked 19th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 3 strong buy ratings, 16 buy ratings, 6 hold ratings, and no sell ratings.

Upside Potential

AbbVie has a consensus price target of $253.43, representing about 19.2% upside from its current price of $212.63.

Amount of Analyst Coverage

AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 13.99%

Earnings Growth

Earnings for AbbVie are expected to grow by 13.99% in the coming year, from $14.30 to $16.30 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AbbVie is 104.74, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.26.

Price to Earnings Ratio vs. Sector

The P/E ratio of AbbVie is 104.74, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.12.

Price to Earnings Growth Ratio

AbbVie has a PEG Ratio of 0.75. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.28% of the float of AbbVie has been sold short.

Short Interest Ratio / Days to Cover

AbbVie has a short interest ratio ("days to cover") of 3.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AbbVie has recently increased by 8.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

AbbVie pays a meaningful dividend of 3.17%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

AbbVie has been increasing its dividend for 53 years.

Dividend Coverage

The dividend payout ratio of AbbVie is 340.89%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, AbbVie will have a dividend payout ratio of 42.45% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.03

News Sentiment

AbbVie has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 50 news articles for AbbVie this week, compared to 12 articles on an average week.

Search Interest

135 people have searched for ABBV on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.

MarketBeat Follows

99 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 183% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,221,519.00 in company stock.

Percentage Held by Insiders

0.06% of the stock of AbbVie is held by insiders.

Percentage Held by Institutions

70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 5/15 Dividend: 4/15/2026
• Ex-Dividend for 5/15 Dividend: 4/15/2026
• Last Earnings: 4/29/2026
• Dividend Payable: 5/15/2026
• Today: 6/02/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:ABBV
• CIK: 1551152
• Web: www.abbvie.com
• Phone: (847) 932-7900
• Fax: 302-655-5049
• Employees: 57,000
• Year Founded: 2013

Price Target and Rating

• Average Price Target for AbbVie: $253.43
• High Price Target: $298.00
• Low Price Target: $214.00
• Potential Upside/Downside: +19.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.03
• Trailing P/E Ratio: 104.62
• Forward P/E Ratio: 14.84
• P/E Growth: 0.75
• Net Income: $4.23 billion
• Net Margins: 5.79%
• Pretax Margin: 9.51%
• Return on Equity: -576.45%
• Return on Assets: 13.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.80
• Quick Ratio: 0.68

Sales & Book Value

• Annual Sales: $62.82 billion
• Price / Sales: 5.97
• Cash Flow: $14.77 per share
• Price / Cash Flow: 14.37
• Book Value: ($1.83) per share
• Price / Book: -115.97

Miscellaneous

• Outstanding Shares: 1,766,793,000
• Free Float: 1,765,733,000
• Market Cap: $374.97 billion
• Optionable: Optionable
• Beta: 0.32